User Fee Formula Does Not Account For Greater Number Of Industry-Requested Meetings, FDA Says
This article was originally published in The Pink Sheet Daily
An agency white paper reports that increasing drug development costs and thinning pipelines are prompting more companies to seek formal advice from FDA in the IND phase, increasing the agency’s workload.
You may also be interested in...
Applications including clinical data will cost $672,000. Applications without clinical data and supplemental applications with clinical data will cost $336,000.
A possible settlement between Merck and tax authorities could be significantly smaller than GlaxoSmithKline's recent settlement with the IRS based on the companies' projected liability
Pfizer's success will depend on its ability to negotiate the paradox of increasing demand for pharmaceuticals coupled with growing attempts to restrain costs, CEO Jeffrey Kindler said